Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1645-1651

  Shin, Jae Uk ^a   Lee, Chang Hoon ^a   Lee, Kyu Taek ^a   Lee, Jong Kyun ^a   Lee, Kwang Hyuck ^a   Kim, Kwang Min ^a   Kim, Kyoung Mee ^a   Park, Sang Mo ^b   Rhee, Jong Chul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

ATM; Cyclin B1; p53; Pancreatic neuroendorcine tumors; Prognosis

Indexed keywords

ATM PROTEIN; CYCLIN B1;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

EID: 84868093697     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0420-5     Document Type: Article

References (25)

1. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727-33.
2. Wang DS, Zhang DS, Qiu MZ, Wang ZQ, Luo HY, Wang FH, et al. Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas. Tumour Biol. 2011;32(4):697-705.
3. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014:13-27.
4. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.
5. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798-803.
6. Chung DC. Cyclin d1 in human neuroendocrine: tumorigenesis. Ann N Y Acad Sci. 2004;1014:209-17.
7. Chung DC, Brown SB, Graeme-Cook F, Seto M, Warshaw AL, Jensen RT, et al. Overexpression of cyclin d1 occurs frequently in human pancreatic endocrine tumors. J Clin Endocrinol Metab. 2000;85:4373-8.
8. Park M, Chae HD, Yun J, Jung M, Kim YS, Kim SH, et al. Constitutive activation of cyclin b1-associated cdc2 kinase overrides p53-mediated g2-m arrest. Cancer Res. 2000;60:542-5.
9. Innocente SA, Abrahamson JL, Cogswell JP, Lee JM. P53 regulates a g2 checkpoint through cyclin b1. Proc Natl Acad Sci USA. 1999;96:2147-52.
10. Igarashi T, Jiang SX, Kameya T, Asamura H, Sato Y, Nagai K, et al. Divergent cyclin b1 expression and rb/p16/cyclin d1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol. 2004;17:1259-67.
11. Teoh N, Pyakurel P, Dan YY, Swisshelm K, Hou J, Mitchell C, et al. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis. Gastroenterology. 2010;138:1155-65. e1-2.
12. Corbo V, Beghelli S, Bersani S, Antonello D, Talamini G, Brunelli M, et al. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann Oncol. 2012;23(1):127-34.
13. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to pi-3 kinase. Science. 1995;268:1749-53.
14. Bose S, Yap LF, Fung M, Starzcynski J, Saleh A, Morgan S, et al. The atm tumour suppressor gene is down-regulated in ebv-associated nasopharyngeal carcinoma. J Pathol. 2009;217:345-52.
15. Kang B, Guo RF, Tan XH, Zhao M, Tang ZB, Lu YY. Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer. Mutat Res. 2008;638:17-25.
16. Xing J, Wu X, Vaporciyan AA, Spitz MR, Gu J. Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and ku heterodimeric regulatory complex 86-kd subunit expression in patients with nonsmall cell lung cancer. Cancer. 2008;112:2756-64.
17. Ye C, Cai Q, Dai Q, Shu XO, Shin A, Gao YT, et al. Expression patterns of the atm gene in mammary tissues and their associations with breast cancer survival. Cancer. 2007;109:1729-35.
18. Grabsch H, Dattani M, Barker L, Maughan N, Maude K, Hansen O, et al. Expression of DNA double-strand break repair proteins atm and brca1 predicts survival in colorectal cancer. Clin Cancer Res. 2006;12:1494-500.
19. Yu G, Zhu MH, Zhu Z, Ni CR, Zheng JM, Li FM. Expression of atm protein and its relationship with p53 in pancreatic carcinoma with tissue array. Pancreas. 2004;28:421-6.
20. Innocente SA, Lee JM. P53 is a nf-y- and p21-independent, sp1-dependent repressor of cyclin b1 transcription. FEBS Lett. 2005;579:1001-7.
21. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, et al. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res. 1996;56:4159-63.
22. Kawamoto H, Koizumi H, Uchikoshi T. Expression of the g2-m checkpoint regulators cyclin b1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Pathol. 1997;150:15-23.
23. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, et al. Overexpression of cyclin b1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 2000;60:4000-4.
24. Hassan KA, Ang KK, El-Naggar AK, Story MD, Lee JI, Liu D, et al. Cyclin b1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res. 2002;62:6414-7.
25. Bjorck E, Ek S, Landgren O, Jerkeman M, Ehinger M, Bjorkholm M, et al. High expression of cyclin b1 predicts a favorable outcome in patients with follicular lymphoma. Blood. 2005;105:2908-15.